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 Retired 
Context: The increased use of diagnostic and therapeutic procedures that involve radiation raises 
concerns about radiation effects, particularly in children and to the radio-sensitive thyroid gland. 
Objectives: Evaluation of relative risk (RR) trends for thyroid radiation doses <0.2 gray; 
evidence of a threshold dose; and possible modifiers of the dose-response, e.g., sex, age at 
exposure, time since exposure. 
Design and setting: Pooled data from nine cohort studies of childhood external radiation 
exposure and thyroid cancer with individualized dose estimates, ≥1,000 irradiated subjects or 
≥10 thyroid cancer cases, with data limited to individuals receiving doses <0.2 gray.   
Participants: Cohorts included: childhood cancer survivors (n=2); children treated for benign 
diseases (n=6); and children who survived the atomic bombings in Japan (n=1). There were 252 
cases and 2,588,559 person-years in irradiated individuals and 142 cases and 1,865,957 person-
years in non-irradiated individuals. 
Intervention: There were no interventions.  
Main Outcome Measure: Incident thyroid cancers.  
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Results: For both <0.2 gray and <0.1 gray, RRs increased with thyroid dose (P<0.01), without 
significant departure from linearity (P=0.77 and P=0.66, respectively).  Estimates of threshold 
dose ranged from 0.0 to 0.03 gray, with an upper 95% confidence bound of 0.04 gray.  The 
increasing dose-response trend persisted >45 years after exposure, was greater at younger age at 
exposure and younger attained age and was similar by sex and number of treatments. 
Conclusions: Our analyses reaffirmed linearity of the dose-response as the most plausible 
relationship for ALARA (“as low as reasonably achievable”) assessments for pediatric low dose 
radiation-associated thyroid cancer risk.   
A pooled analysis of 9 cohorts confirms linearity of childhood thyroid radiation dose and thyroid cancer at 
low radiation doses (<0.2 Gy). Risks arise within 5-10 years and persist for 45+ years. 
A pooling of nine cohort studies of childhood external radiation exposure revealed a linear increase in risk 
of thyroid cancer and reaffirmed the “as low as reasonably achievable” principal for pediatric low dose 
radiation.   
 The increasing use of diagnostic and therapeutic medical procedures that involve 
radiation raises concerns about the consequences of low dose irradiation on cancer occurrence 
and in particular whether linear-based extrapolations represent the best estimate of low dose 
cancer risk or whether a threshold dose, below which there is no risk of radiation-induced cancer, 
might exist (1-3) (see http://dels.nas.edu/Upcoming-Event/Planning-Towards-BEIR-VIII-
Report/AUTO-0-14-84-B).  With increased radiation exposures of children and the well-
documented radio-sensitivity of the thyroid gland, data on thyroid cancer incidence among low 
dose thyroid irradiated children provide an opportunity to address issues of pediatric radiation-
associated thyroid cancer risk in relation to assessments of ALARA (“as low as reasonably 
achievable”), with implications for both clinical practice and radio-epidemiology (3-7).  With 
these considerations in mind, we pool epidemiologic studies on children exposed to external 
radiation and analyze thyroid cancer incidence for those exposed at low doses. 
 A recent pooling of 12 epidemiologic studies of thyroid cancer following radiation 
exposure in childhood included a broad range of thyroid radiation doses, from <0.1 gray (Gy) for 
treatment of benign diseases and exposures following the atomic bombings in Japan to >60 Gy 
resulting from radiation therapies for various childhood cancers (8).  Analyses revealed a 
curvilinear relationship, with relative risks (RR) increasing supra-linearly through about 2-4 Gy, 
leveling at doses between 10-30 Gy with RRs of 30 to 40 and declining thereafter, with RRs 
remaining 5 to 10 at 50-60 Gy.  The leveling and downturn at higher doses may have reflected 
cell killing effects, although compensatory accelerated stem cell repopulation may have partially 
mitigated the decline (9).  The pooled analysis reported increased RRs for doses <0.1 Gy, but did 
not fully explore the result (8).  Investigators also identified important modifiers of the dose-
response association, namely, radiation dose response trends emerged within 5-10 years of 
exposure, increased at younger ages at exposure, declined with increasing attained age and 
persisted for 50 years and more after exposure (8, 10).  Trends were comparable in strength for 
females and males.  Notably, these analyses did not address whether patterns of effect 
modification derived exclusively from those exposed at moderate and high doses or whether 
there were similar patterns among those exposed only at lower doses.  
 Questions about thyroid cancer risks at low thyroid radiation doses in children are best 
addressed using data in children exposed at low doses.  We therefore examined data in children 
exposed at low doses to consider: (i) RR patterns at doses <0.2 Gy and <0.1 Gy; (ii) the possible 
existence of a threshold dose; and (iii) modification of the dose-response by sex, age at exposure, 
attained age, years since exposure and radiation dose fractionation.  
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
AD
VA
NC
E 
AR
TI
CL
E
The Journal of Clinical Endocrinology & Metabolism; Copyright 2017  DOI: 10.1210/jc.2016-3529 
 
 
3 
METHODS 
Study populations 
 We used MEDLINE to identify 12 epidemiologic (10 cohort and two case-control) 
studies of childhood external radiation exposure and thyroid cancer and approached the principal 
investigators to collaborate in a pooled data analysis.  We required that studies had sufficient 
information for the calculation of individualized, quantitative, thyroid gland-specific dose 
estimates and enrolled at least 1,000 irradiated subjects or 10 thyroid cancers (8).   Given the 
highly specialized characteristics of the studies and, for cohorts, the need to accommodate 
continued follow-up, we were confident that these studies represented all eligible studies.  After 
the pooling of data and harmonization of variables, the current analysis restricted data to doses 
<0.2 Gy, except where noted.  This resulted in the exclusion of two case-control studies 
following treatment for childhood cancer (11, 12) and one cohort study of childhood lymphoid 
hyperplasia (13).  Since there were no thyroid cancer cases <0.2 Gy, except for one non-exposed 
case for one study (11), and since analyses adjusted for study, the three omitted studies provided 
no information for the evaluation of RR patterns. Nine cohorts remained, including treatment for 
childhood cancer (n=2), treatment for various benign diseases (e.g., tinea capitis, enlarged 
thymus, hemangioma and enlarged tonsils and adenoids) (n=6), and Japanese atomic bomb 
survivors (n=1) (Appendix Table 1).  Detailed study-specific descriptions and study-specific 
analyses are found in reference (8) and its Supplemental Material.  Cases were those who 
developed incident thyroid cancer during follow-up.  Excluding non-melanoma skin cancer, 
cases represented first primary cancers for studies of benign diseases and atomic bomb survivors 
and second primary cancers for studies of childhood cancer survivors.  We censored autopsy-
identified thyroid cancers at death, but did not include them as cases.  
The institutional review boards approved each participating study and the data pooling. 
Models for thyroid cancer risk 
 For seven cohorts, follow-up started at date of first radiation exposure or enrollment for 
non-exposed (Appendix Table 1).  For the Atomic Bomb Survivors study, follow-up started in 
1958, 13 years after exposure.  For the Childhood Cancer Survivor Study (CCSS) cohorts, 
follow-up started five (CCSS-US) or three years (CCSS-Fr/UK) after first cancer.  Follow-up 
continued to the earliest date of death, loss to follow-up, incident cancer other than non-
melanoma skin cancer or end of study. 
 Analyses used Poisson regression, with person-years of follow-up cross-tabulated by 
study, sex, age at exposure, calendar year of follow-up, time since exposure, attained age, 
treatment with chemotherapy, thyroid radiation dose and number of radiation treatments, where 
one treatment encompassed all doses within six months.  Regressions adjusted for study, sex and 
age and selected study-specific variables.  For the Israel Tinea Capitis study, variables included 
country of origin (North Africa/Others) and comparison group (sibling/population).  For the 
Rochester Thymus study, variables included the presence of goiter (yes/no) and Jewish religion 
(yes/no).  For the Atomic Bomb Survivors study, variables included city of exposure 
(Hiroshima/Nagasaki), not in city at the bombing (yes/no) and enrollment in the Adult Health 
Study (yes/no), the latter variable accounting for possible surveillance-related differences in 
thyroid cancer rates (10). For CCSS cohorts, additional variables included type of first cancer 
(Hodgkin lymphoma or other) and chemotherapy treatment.  Since most radiation-exposed cases 
had only one treatment (84%), we assumed one treatment for exposed patients who were missing 
number of treatments.  We computed person-years weighted means within each cell of the cross-
tabulation for continuous variables.  
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 The Appendix provides methodologic details.  The regression model for thyroid cancer 
incidence rate, r( , , )x d c , included adjustment variables x, thyroid radiation dose d and 
chemotherapy exposure c.  We previously determined that an additive relationship best described 
the joint association of radiation exposure and chemotherapy treatment (c =1 if yes and c =0 if 
no).  Given x, the incidence rate under an additive relationship for radiation dose and 
chemotherapy, termed non-synergistic, is the sum of three terms: the incidence rate absent both 
factors, r( , 0, 0)x , and the excess rates for each exposure at the referent level of the other, 
( ) ( ){ }r , , 0 r , 0, 0x d x−  and ( ) ( ){ }r , 0, r , 0, 0x c x−  (14, 15), i.e.,   
 
( ) ( ) ( ) ( ){ } ( ) ( )r , ,  r , 0, 0 r , , 0 r , 0, 0 {r , 0, r , 0, 0 } x d c x x d x x c x= + − + −  
Factoring the non-exposed thyroid cancer rate, ( )0 ( )  r , 0, 0r x x= ,  
0( , , )  ( ) {1  ( )   }r x d c r x ERR d cθ= + +           (1) 
where ERR(d) was the radiation-associated excess relative risk (ERR) and θ was the 
chemotherapy-associated ERR.  We set 0 ( ) (  )r x exp xφ=  with ϕ a vector of parameters.  For <0.2 
Gy, we fitted a simple linear model, ( )   ERR d dβ= , where β was the ERR/Gy, i.e., the slope.  We 
examined departures from linearity with likelihood ratio tests and used a likelihood-based 95% 
confidence interval (CI) for estimates of β.   
 A threshold identifies a dose below which there is no radiation effect, while a linear 
threshold model specifies a linear relationship starting at the threshold dose, i.e., 
( )   ( )ERR d dβ η += − , where ( ) max(0, )d dη η+− = −  with η the unknown threshold.  We 
compared deviances to identify the maximum likelihood estimate for the threshold.  We also 
modeled the dose-response using a 4-knot cubic spline (16, 17).  Finally, we compared the full 
dose range model (8), but fitted to the nine cohorts in this analysis. 
 We used the Epicure program for all modeling (18). 
RESULTS 
For doses <0.2 Gy and <0.1 Gy, there were 252 and 184 radiation-exposed thyroid cancer cases, 
respectively, and 2,588,559 and 2,114,683 person-years of follow-up (Appendix Table 1).  
Among non-exposed individuals, there were 142 thyroid cancer cases and 1,865,957 person-
years. 
Radiation dose-response 
 For doses <0.2 Gy, RRs increased significantly with radiation dose (Table 1 and Figure 1, 
main panel, solid black line) (P<0.01), with no significant departure from linearity (P=0.77).  A 
moving-average smoothing of RRs (thick grey line) with plus and minus one standard deviation 
(thin grey line) highlighted the linear pattern.  The downward extrapolation from the curvilinear 
model fitted to the full dose range closely approximated low dose RRs (dash line).  Results were 
similar for <0.1 Gy (inset panel), with no departure from linearity (P=0.66).  
 For <0.2 Gy and <0.1 Gy, estimates of β were 11.1 (95% CI, 6.6, 19.7) and 9.6 (95% CI, 
3.7, 17.0), respectively, with fitted RRs at 0.2 Gy of 3.2 (95% CI, 2.3, 4.3) and 2.9 (95% CI, 1.7, 
4.5).  Using the full dose range model, the fitted RR at 0.2 Gy was 2.7 (95% CI, 2.1, 3.4).  
 The cubic spline was flat through 0.03 Gy (Figure 1, dot line), largely influenced by the 
RR of 0.9 (95% CI, 0.5,1.6) for the 0.02-0.03 Gy dose category with 13 cases (Table 1).  
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Nonetheless, the simple linear model had the minimum Akaike Information Criterion (19), 
identifying it as the preferred model.   
Estimates of a threshold dose 
 We examined deviances to estimate threshold dose (η).  For <0.2 Gy, deviances (open 
circle) and a moving-average smoothing (solid line) increased (i.e., poorer fit) with possible 
threshold values, with minimum deviance (star symbol) at 0.00 Gy (Figure 2, main panel).  
Deviances changed little through 0.02 Gy.  For <0.1 Gy, the minimum deviance occurred at 
0.025 Gy, with no change through 0.03 Gy (inset panel), indicating limited ability to identify a 
specific threshold.  One-sided upper 95% CIs were 0.036 Gy for <0.2 Gy and 0.044 for <0.01 Gy 
(dash line).  
Excess radiation-associated thyroid cancers 
 Using the equation for doses <0.2 Gy, we estimated 37.2% radiation-associated thyroid 
cases (252 observed with 93.8 excess exposed cases) (Table 1).  This varied from 5.7% (54 
observed with 3.1 excess cases) for doses <0.02 Gy to 54.4% (68 observed with 37.0 excess 
cases) for doses between 0.1 and 0.2 Gy. 
Modification of the radiation dose-response 
 The radiation dose-response was similar by sex (P=0.35) and number of treatments 
(P=0.25) (Table 2).  The dose-response generally increased with younger age at exposure, except 
for those exposed under age one year (P=0.01).  Radiation dose-responses decreased with greater 
attained age (P=0.01) and decreased but remained elevated with years since exposure (P=0.02), 
persisting 45 years and more after irradiation.  Appendix Figure 1 displays fitted RRs at 0.2 Gy 
and models using continuous modifiers, illustrating the wide confidence interval for the RR 
under age one year.  These effect modification patterns were similar for doses <0.1 Gy (Table 2), 
though estimates were less stable.  Results paralleled those in the complete data (8).  
Consistency of radiation effects across cohorts 
 We evaluated the influence of each study, with particular attention to the Tinea Capitis 
study and the Atomic Bomb Survivors study, since they contributed 52% (132/252) and 28% 
(70/252) of exposed cases, respectively.  For <0.2 Gy and with an adjustment to reflect age five 
years at exposure to account for cohort differences, the fitted RR at 0.2 Gy was 3.2 (95% CI, 2.4, 
4.5) for all studies combined (Figure 3, upper panel).  With the Tinea Capitis study omitted, the 
fitted RR estimate at 0.2 Gy decreased 31% to 2.2 (95% CI, 1.5, 4.0) and with the Atomic Bomb 
Survivors study omitted, the estimate increased 25% to 4.0 (95% CI, 2.8, 6.1).  Omitting other 
studies individually, as well as both CCSS cohorts, did not alter the summary estimate.  For <0.1 
Gy, the Tinea Capitis and Atomic Bomb Survivors studies contributed 82% (150/282) of 
exposed cases and omission of each study resulted in similar consequences.  
 We assumed the same ERR/Gy applied in all study populations. Allowing random effects 
for ERR/Gy (β) due to population differences and adjusting for age at exposure, Cochran’s Q-
statistics were P=0.89 for doses <0.2 Gy and P=0.95 for doses <0.1 Gy indicating homogeneity 
of the ERR/Gy across studies (20-22).  The random effects fitted RRs at 0.2 Gy were 3.0 (95% 
CI, 2.1, 4.9) for <0.2 Gy and 2.9 (95% CI, 1.7, 6.6) for <0.1 Gy.   
Discussion 
 Given enhanced effects for childhood radiation exposures and the well-documented 
radio-sensitivity of the thyroid gland, our pooling of all epidemiologic data with thyroid radiation 
doses <0.2 Gy enabled a direct assessment of a linear dose-response relationship for thyroid 
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cancer risk and of a possible threshold dose.  The analysis included 252 radiation exposed 
thyroid cancer cases and was the most definitive to date of thyroid cancer following low dose 
external radiation exposure. 
 For <0.2 Gy and <0.1 Gy, RRs increased significantly with thyroid radiation dose, with 
trends consistent with linearity.  Fitted estimates of RRs at these doses were also consistent with 
downward extrapolations with previous models based on all doses through 70+ Gy.  
Consequently, our results refute suggestions of no excess radiation-related thyroid cancer risk 
below these a priori restriction levels and support linearity in ALARA assessments.   
 Estimates of a threshold dose were 0.0 Gy for <0.2 Gy and 0.03 Gy for <0.1 Gy.  These 
estimates derived from the likelihood profile and therefore represented maximum likelihood 
estimates (23).  One-sided upper 95% confidence limits were 0.036 Gy and 0.044 Gy, 
respectively.  Analysis did not account for dose measurement error, which may have introduced 
bias, typically an underestimation (24, 25).  However, for the Atomic Bomb Survivors study, we 
used measurement error-adjusted dose estimates (26, 27).  For the Tinea Capitis study, an 
analysis that accounted for measurement error estimated a similar dose response and assessment 
of effect modifiers (28, 29).  With the Tinea Capitis and the Atomic Bomb Survivors studies 
comprising 80% of exposed cases and 57% of exposed person-years, it was thus unlikely that 
measurement error substantially affected estimates of threshold dose, although a definitive 
conclusion was not possible. 
 A comprehensive accounting of dose measurement error for all studies was beyond the 
scope of this paper.  In particular, we did not know to what extent dosimetric conditions of the 
Tinea Capitis study applied to other studies.  Nevertheless, we note one potential contribution to 
dose measurement error for some CCSS participants, namely, an underestimation of thyroid dose 
from additional radiological examinations associated with cancer diagnosis, treatment 
monitoring and follow-up.  This additional dose, more likely with head and neck cancers, was 
not captured in the dose assessments and may have amounted to 0.2 Gy and more.  Since CCSS 
cohorts included 5% of cases and 3% of person-years and since influence analysis indicated 
minimal impact from the omission of CCSS studies, any underestimation of radiation doses in 
CCSS data likely involved minimal bias. 
 The 12-study pooled analysis supported a minimum latency of 5-10 years (8).  For 5-9, 
10-14 and 15-19 years since exposure, there were 39, 65 and 128 exposed thyroid cancers, 
respectively, and fitted RRs at 0.2 Gy were 1.7, 1.9 and 3.3.  For <5 years since exposure, there 
were three cases and the RR was not estimable.  An important question was whether a similar 
latency applied for those exposed only at low doses.  For <0.2 Gy, there were 3, 13 and 20 
exposed cases for 5-9, 10-14 and 15-19 years since exposure, respectively, and fitted RRs at 0.2 
Gy were 2.9 (95% CI, <0.0, 11.7), 6.2 (95% CI, 2.8, 13.5) and 5.5 (95% CI, 2.6, 10.6).  For <0.1 
Gy, there were 3, 10 and 8 exposed cases in the time since exposure categories and estimated 
RRs at 0.2 Gy were 3.5 (95% CI, 0.7, 11.1), 4.8 (95% CI, 1.8, 10.5) and 1.6 (95% CI, 0.3, 4.1).  
While data were limited, fitted RRs in the restricted data appeared compatible with a minimum 
latency of 5-10 years. 
 We previously identified an additive (non-synergistic) relationship for the RRs of thyroid 
radiation dose and chemotherapy for childhood cancer and thyroid cancer incidence (8).  We 
refitted models for two subsets of the data to remove any residual uncertainty about a non-
synergistic relationship chemotherapy: (i) participants who did not receive chemotherapy; and (ii) 
participants in the seven non-CCSS studies.  The estimated ERR/Gy was 11.0 for participants 
without chemotherapy and 11.1 for the seven cohorts, resulting in fitted RRs at 0.2 Gy of 3.2 for both 
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subsets.  This equaled the fitted RR of 3.2 for data with doses <0.2 Gy, indicating choice of risk 
model for chemotherapy did not impact results. 
 Vaccarella et al have suggested that increased medical surveillance and new diagnostic 
techniques are important factors in recent worldwide increases in the incidence rates for thyroid 
cancer (30).  While medical screening may have increased the ascertainment of thyroid cancer 
cases, there was little reason to presuppose that increased screening was also related to radiation 
dose and thus acted to confound our results.   Information on thyroid cancer screening practices 
was not explicitly available for all studies in our pooling; however, analytic evaluation was 
possible in two studies.   Ron et al. considered the effect of screening using surrogate 
information on the potential for heightened medical surveillance in the Atomic Bomb Survivors 
Study and the Michael Reese Hospital Study (10).  For the former, Ron et al evaluated 
participation in the Adult Health Study, a companion study starting in 1958 that involved 
approximately 20% of subjects who were invited to biennial clinical examinations.  For the 
latter, Ron et al used calendar year 1974 as an approximate indicator year for the start of 
heightened public awareness of radiation effects and heightened surveillance.  Analyses revealed 
the expected increase in the absolute rate of thyroid cancer incidence, but also found no 
significant variation in the radiation dose-response for the RR of thyroid cancer (10).  In the 
current analysis of restricted data, we similarly found no significant variation in the linear 
radiation dose-response parameter by participation in the Adult Health Study for the Atomic 
Bomb Survivor Study (P=0.39).  With one case, we could not assess the Michael Reese Hospital 
Study.  We also evaluated variation of the radiation dose-response across categories of calendar 
year of follow-up, reasoning that confounding from enhanced thyroid screening was more likely 
to have occurred in recent years.  After adjustment for attained age, we found no significant 
variation of the radiation dose-response by calendar year (P=0.32).       
 With the nuclear releases from the 1986 Chernobyl power plant accident and from the 
Fukushima Daiichi power plant following the 2011 Great East Japan Earthquake and Tsunami, 
there are questions about comparative thyroid cancer risks for childhood exposure to low radiation 
doses from external and internal sources.  External sources of exposure derive mainly from x and γ-
irradiation, while internal sources derive mainly from short-lived β-radiation decay of iodine-131 
(1, 31-35).  Studies of thyroid cancer in children exposed following the Chernobyl accident have 
reported a range of RRs.  RR estimates at 0.2 Gy were 1.9 from a Russian Federation-Belarus study 
(36), 1.9 from a Ukraine study (37), with a more recent estimate of 1.2 (38), and 1.2 from a 
Belarus study (39).  Our analysis of external thyroid radiation dose yielded an estimate of 3.2 (95% 
CI, 2.3, 4.3).  For those aged <5 years at exposure, RR estimates at 0.2 Gy were 2.6 in the Ukraine 
study (37) and 1.9 in the Belarus study (39), while our estimate was 3.4 (95% CI, 2.0, 4.8).  These 
results suggested the possibility of a slightly greater thyroid cancer risk from childhood external 
irradiation.  Definitive conclusions are problematic due to the substantial differences between our 
populations of medically exposed individuals and atomic bomb survivors and the Chernobyl-exposed 
populations who were mildly to moderately iodine deficient and/or intensely screened (40). 
 The use of computed tomography (CT) scanning for medical diagnostic and therapeutic 
procedures has increased substantially in recent years in both adults and children, with children 
in the U.S. now receiving 5 to 9 million scans per year (41, 42) (http://www.cancer.gov/about-
cancer/causes-prevention/risk/radiation/pediatric-ct-scans).  CT scans of children can result in 
thyroid radiation doses of 0.010 Gy for head CTs (38, 43), 0.027 Gy for chest CTs (43-45), 0.050 
Gy for neck CTs (46, 47), 0.036 Gy for cervical spine CTs (48) and 0.008 Gy for abdominal CTs 
(43).  With CT scans often repeated, multi-detector row CT scans reducing scan times and 
enabling increased use of CT scans in pediatric medicine and the use of multi-phase (repeat 
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scanning before and after contrast injection) CT examinations, there is a high potential for 
pediatric patients to receive thyroid doses for which there is a demonstrably increased risk of 
thyroid cancer. 
 For a given total dose, the number of radiation treatments did not modify risks, although 
numbers of thyroid cancer cases with multiple treatments were limited (the Israel Tinea study, 
Hemangioma-Stockholm study and Hemangioma-Göteborg study contributed 10, 9 and 1 cases, 
respectively).  Pooled analyses of seven studies, a subset of the current studies (10), 12 studies 
across the full range of doses including 144 cases with multiple treatments (8), and our current 
analysis do not support a significant dose fractionation effect.  Notably, these analyses did observe a 
reduced strength of association with multiple radiation treatments, albeit not statistically significant.  
Harmonization of fractionation data was challenging due to diverse and calendar year varying 
treatment protocols and limited information on treatment specifics for the studies.  Various 
definitions of dose fraction were possible.  Due to harmonization necessities, we defined one 
treatment as all radiation doses received within six months. This resulted in the large majority of 
patients receiving one radiation “treatment”, diminishing our ability to evaluate fractionation.  
In conclusion, these analyses reinforced the existence of an excess thyroid cancer risk at 
doses <0.2 Gy and <0.1 Gy, and perhaps at even lower doses.   The consistency of the linear 
radiation dose-response at low doses and the apparent absence of a significant radiation 
fractionation effect reaffirm that the direct application of a linear relationship remains the most 
plausible approach for the extrapolation of radiation-associated thyroid cancer risk (49) and adds 
support to the use of a linear model for ALARA assessments (50).  
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Figure 1: Category-specific relative risks (RR) of thyroid cancer by thyroid radiation dose (solid 
symbol) with 95% confidence intervals, a moving-average smoothing (grey line) and plus/minus 
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one standard deviation (thin grey line), the fitted linear excess relative risk model (solid black 
line) and a restricted cubic spline (dash-dot-dot line).  Data pooled from nine cohort studies and 
limited to <0.2 Gy (main panel) or <0.1 Gy (inset).  Also, the linear-exponential-linear model 
(Appendix equation 3) fitted to all data with the full range of doses (dash line).   
Figure 2: Deviances for linear excess relative risk models given a threshold dose (η) (open 
symbol) (see text for model), with deviances rescaled to zero at the minimum deviance (star 
symbol), and a moving average smoothing.  Dash line identifies one-sided 95% confidence limit.  
Data pooled from nine cohort studies and limited to <0.2 Gy (main panel) and <0.1 Gy (inset). 
Figure 3: Fitted RRs at 0.2 and 0.1 Gy and 95% CIs under a linear excess relative risk model 
with effect modification by the natural logarithm of age at exposure divided by 5 years overall 
and sequentially omitting one study at a time.  RRs reflect age five years at exposure.  Dash line 
represents lower and upper confidence limits for all data. 
Table 1: Numbers of thyroid cancer cases, participants, person-years (P-yrs) of follow-up, 
relative risks (RR), 95% confidence intervals (CI) and estimated radiation-associated excess 
cases.  Pooled data for doses <0.2 Gy. 
Dose (gray)       
Range Mean Cases Participants P-yrs RR a 95% CI Excess b 
0 0.000 142 46,439 1,865,957 1.00  0.0 
0.001-0.004 0.002 24 9,464 367,606 1.07 (0.7,1.8) 0.4 
0.005-0.02 0.009 30 13,796 587,614 1.21 (0.8,1.9) 2.7 
0.02-0.03 0.025 13 8,055 345,748 0.87 (0.5,1.6) 4.6 
0.04-0.06 0.049 54 7,204 315,014 2.01 (1.4,2.8) 15.0 
0.06-0.08 0.068 31 5,825 256,456 1.40 (0.9,2.1) 16.9 
0.08-0.09 0.088 32 5,535 242,247 1.78 (1.2,2.7) 17.3 
0.10-0.12 0.107 20 3,220 136,943 2.51 (1.5,4.1) 9.4 
0.12-0.14 0.126 21 3,537 149,525 2.63 (1.6,4.2) 11.0 
0.14-0.16 0.146 13 1,778 73,824 3.76 (2.1,6.8) 5.5 
0.16-0.19 0.177 14 2,741 113,582 2.41 (1.4,4.3) 11.1 
Total  394 107,594 4,454,516   93.8 
a
 Relative risks adjusted for study, sex, age, other study-specific factors and chemotherapy exposure.  
b
 Estimated excess number of thyroid cancer cases above fitted background of non-exposed participants. 
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Table 2:  Evaluation of effect modification for the thyroid cancer radiation dose response, 
including numbers of radiation exposed cases and fitted relative risks (RR) at 0.2 Gy under an 
additive adjustment for treatment with chemotherapy a.  Pooled data limited to doses <0.2 Gy or 
<0.1 Gy. 
Modifier Cases RR0.2 Gyb θ Cases RR0.2Gyb θ 
 Data with doses < 0.2 Gy Data with doses < 0.1 Gy 
None 252 3.2 2.84 184 2.9 2.17 
Gender       
Male 58 4.2 2.93 44 5.0 2.31 
Female 194 3.0  140 2.4  
P-value c  0.35   0.15  
Age at exposure (years)     
<1 40 1.6 3.49 30 0.4 2.77 
1-4 64 4.2  31 2.9  
5-9 84 3.9  71 3.9  
10-14 42 3.5  35 3.7  
15-19 22 1.6  17 0.6  
P-value d  0.01   0.05  
Attained age (years)      
<20 17 9.4 3.72 10 7.5 2.49 
20-29 43 5.5  25 4.1  
30-39 48 2.6  33 2.0  
40-49 60 2.2  48 2.6  
50-59 62 3.1  52 3.2  
60+ 22 2.5  16 1.9  
P-value d  0.01   0.13  
Time since exposure (years)     
<20 37 5.3 3.16 22 4.2 2.41 
20-29 49 3.5  36 3.5  
30-34 33 3.4  22 1.7  
35-39 33 3.3  22 2.3  
40-44 36 2.4  28 2.2  
45+ 64 2.3  54 3.2  
P-value d  0.02   0.26  
Number of treatments e      
1 226 3.5 2.80 170 3.4 2.13 
≥2 20 2.4  8 0.4  
P-value c  0.25   0.25  
a
 Fitted RRs from a linear model in radiation dose with an additive effect for chemotherapy treatment, c, 
( )RR , 1 β   td x d cθ= + + .  Models adjusted for study, sex, age and study-specific factors (see text). For 
modifiers, (   j jj zβ∑  d) replaced βd where zj was an indicator variable for category j and βj was a linear 
parameter. There were 142 with non-exposed cases.  For <0.2 Gy and <0.1 Gy, β estimates with 95% confidence 
interval were 11.1 (6.6, 19.7) and 9.6 (3.7, 17.0), respectively. 
b Fitted RR at 0.2 Gy.
  
c
 P-value for likelihood ratio test of no variation based on a binary modifier. 
d
 P-value for likelihood ratio test of no variation based on continuous modifier.
 
e The definition of fractionation, which involved time between fractions, dose per fraction and reason, varied by 
study. One treatment included all dose fractions received within six months in most studies and within one year for 
the Tinea Capitis study. 
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